152 related articles for article (PubMed ID: 36997081)
1. The effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study.
Lazorwitz A; Sheeder J; Teal S
Contraception; 2023 Jul; 123():110035. PubMed ID: 36997081
[TBL] [Abstract][Full Text] [Related]
2. The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users.
Lazorwitz A; Davis A; Swartz M; Guiahi M
Contraception; 2017 Jun; 95(6):571-577. PubMed ID: 28288788
[TBL] [Abstract][Full Text] [Related]
3. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.
McNicholas C; Swor E; Wan L; Peipert JF
Am J Obstet Gynecol; 2017 Jun; 216(6):586.e1-586.e6. PubMed ID: 28147241
[TBL] [Abstract][Full Text] [Related]
4. Effect of Topiramate on Serum Etonogestrel Concentrations Among Contraceptive Implant Users.
Lazorwitz A; Pena M; Sheeder J; Teal S
Obstet Gynecol; 2022 Apr; 139(4):579-587. PubMed ID: 35594123
[TBL] [Abstract][Full Text] [Related]
5. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.
Ali M; Akin A; Bahamondes L; Brache V; Habib N; Landoulsi S; Hubacher D;
Hum Reprod; 2016 Nov; 31(11):2491-2498. PubMed ID: 27671673
[TBL] [Abstract][Full Text] [Related]
6. Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users.
Lazorwitz A; Aquilante CL; Sheeder J; Guiahi M; Teal S
Contraception; 2019 Jul; 100(1):37-41. PubMed ID: 30980827
[TBL] [Abstract][Full Text] [Related]
7. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
[TBL] [Abstract][Full Text] [Related]
8. Pilot study of a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant.
Clure C; Sheeder J; Lazorwitz A
Contraception; 2024 Jul; 135():110442. PubMed ID: 38552822
[TBL] [Abstract][Full Text] [Related]
9. A pilot study on the effect of isotretinoin on serum etonogestrel concentrations in contraceptive implant users.
Lazorwitz A; Seale R; Davis A; Guiahi M
Contraception; 2020 Jul; 102(1):58-60. PubMed ID: 32325076
[TBL] [Abstract][Full Text] [Related]
10. An exploratory study on the possible association of serum etonogestrel concentrations with mood concerns and symptoms among contraceptive implant users.
Diamond B; Sheeder J; Lazorwitz A
Contraception; 2024 Jan; 129():110298. PubMed ID: 37802462
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen for the treatment of breakthrough bleeding with the etonogestrel implant: a randomized controlled trial.
Simmons KB; Edelman AB; Fu R; Jensen JT
Contraception; 2017 Feb; 95(2):198-204. PubMed ID: 27725164
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of double vs single-dose etonogestrel implant to overcome the interaction with efavirenz-based antiretroviral therapy.
Chappell CA; Lamorde M; Nakalema S; Kyohairwe I; Byakika-Kibwika P; Meyn LA; Pham MM; Scarsi KK
Am J Obstet Gynecol; 2024 Mar; ():. PubMed ID: 38458408
[TBL] [Abstract][Full Text] [Related]
13. A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement.
Bahamondes L; Brache V; Ali M; Habib N;
Contraception; 2018 Sep; 98(3):181-187. PubMed ID: 29777663
[TBL] [Abstract][Full Text] [Related]
14. Variability in repeat serum etonogestrel concentrations among contraceptive implant users during the steady-release pharmacokinetic period.
Lazorwitz A; Sheeder J; Teal S
Contraception; 2022 Apr; 108():65-68. PubMed ID: 34973207
[TBL] [Abstract][Full Text] [Related]
15. Etonogestrel concentrations among contraceptive implant users in Botswana using and not using dolutegravir-based antiretroviral therapy.
Bishop IJ; Gertz AM; Simon B; Tawe L; Lechiile K; Liu S; Teodoro N; Mussa A; Avalos A; Malima S; Maotwe T; Mokganya L; Westhoff CL; Morroni C
Contraception; 2020 Sep; 102(3):174-179. PubMed ID: 32387328
[TBL] [Abstract][Full Text] [Related]
16. Changes in body composition in women using long-acting reversible contraception.
Silva Dos Santos PN; Madden T; Omvig K; Peipert JF
Contraception; 2017 Apr; 95(4):382-389. PubMed ID: 28041992
[TBL] [Abstract][Full Text] [Related]
17. Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the U.S. Food and Drug Administration-approved duration.
McNicholas C; Maddipati R; Zhao Q; Swor E; Peipert JF
Obstet Gynecol; 2015 Mar; 125(3):599-604. PubMed ID: 25730221
[TBL] [Abstract][Full Text] [Related]
18. Influence of Genetic Variants on Steady-State Etonogestrel Concentrations Among Contraceptive Implant Users.
Lazorwitz A; Aquilante CL; Oreschak K; Sheeder J; Guiahi M; Teal S
Obstet Gynecol; 2019 Apr; 133(4):783-794. PubMed ID: 30870275
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic evaluation of the etonogestrel contraceptive implant initiated midcycle with and without ulipristal acetate: An exploratory study.
Gawron LM; Kaiser JE; Gero A; Sanders JN; Johnstone EB; Turok DK
Contraception; 2024 Apr; 132():110370. PubMed ID: 38232940
[TBL] [Abstract][Full Text] [Related]
20. Impact of etonogestrel implant use on T-cell and cytokine profiles in the female genital tract and blood.
Haddad LB; Swaims-Kohlmeier A; Mehta CC; Haaland RE; Brown NL; Sheth AN; Chien H; Titanji K; Achilles SL; Lupo D; Hart CE; Ofotokun I
PLoS One; 2020; 15(3):e0230473. PubMed ID: 32214321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
